{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:27:37Z","timestamp":1790814457023,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-05751-1","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T11:02:22Z","timestamp":1729508542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of immunosuppressants and monoclonal antibodies in adults with myasthenia gravis: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Jian","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"issue":"1","key":"5751_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"5751_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol"},{"key":"5751_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Autoantibody specificities in Myasthenia gravis; implications for Improved Diagnostics and therapeutics. Front Immunol. 2020;11:212.","journal-title":"Front Immunol"},{"issue":"9","key":"5751_CR4","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","volume":"12","author":"JJ Verschuuren","year":"2013","unstructured":"Verschuuren JJ, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev. 2013;12(9):918\u201323.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"5751_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"AM Bubuioc","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7\u201316.","journal-title":"J Med Life"},{"issue":"4","key":"5751_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/ane.12270","volume":"130","author":"P Joensen","year":"2014","unstructured":"Joensen P. Myasthenia gravis incidence in a general North Atlantic isolated population. Acta Neurol Scand. 2014;130(4):222\u20138.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"5751_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"3","key":"5751_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International Consensus Guidance for Management of Myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"21","key":"5751_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.21037\/atm-22-2543","volume":"10","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Ge H, Gui M, Yang M, Bi Z, Ma X, et al. Polymorphisms in drug metabolism genes predict the risk of refractory myasthenia gravis. Ann Transl Med. 2022;10(21):1155.","journal-title":"Ann Transl Med"},{"issue":"2","key":"5751_CR10","first-page":"255","volume":"86","author":"J Suh","year":"2013","unstructured":"Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013;86(2):255\u201360.","journal-title":"Yale J Biol Med"},{"issue":"4","key":"5751_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014;15(4):167\u201378.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"8","key":"5751_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865\u201387.","journal-title":"Drugs"},{"issue":"3","key":"5751_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s13311-022-01220-z","volume":"19","author":"R Zeng","year":"2022","unstructured":"Zeng R, Glaubitz S, Schmidt J. Antibody therapies in Autoimmune Inflammatory myopathies: Promising Treatment options. Neurotherapeutics. 2022;19(3):911\u201321.","journal-title":"Neurotherapeutics"},{"key":"5751_CR14","unstructured":"ALEXION. Fda Approves Soliris\u00ae (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (Gmg) 2017 [ https:\/\/myasthenia.org\/Portals\/0\/Press%20Release%20Soliris%20FDA%20Approval.pdf"},{"key":"5751_CR15","unstructured":"AstraZeneca. Ultomiris Approved in the Us for Adults with Generalised Myasthenia Gravis 2022 [ https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/ultomiris-approved-in-the-us-for-adults-with-generalisedmyasthenia-gravis.html"},{"key":"5751_CR16","unstructured":"U N, UCB Announces US. FDA Approval of Rystiggo[\u00ae] (RozanolixizumabNoli) for the Treatment of Adults with Generalized Myasthenia Gravis 2023 [ https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-USFDA-approval-of-RYSTIGGOR-rozanolixizumab-noli-for-the-treatment-of-adultswith-generalized-myasthenia-gravis"},{"key":"5751_CR17","unstructured":"Argenx. Argenx Announces US. Food and Drug Administration Approval of Vyvgart Hytrulo (Efgartigimod Alfa and Hyaluronidase-Qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis 2023 [ https:\/\/www.globenewswire.com\/news-release\/2023\/06\/20\/2691658\/0\/en\/argenx-AnnouncesU-S-Food-and-Drug-Administration-Approval-of-VYVGART-Hytrulo-efgartigimodalfa-and-hyaluronidase-qvfc-Injection-for-Subcutaneous-Use-in-GeneralizedMyasthenia-Grav.html"},{"issue":"1","key":"5751_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12(1):103\u201311.","journal-title":"Intern Emerg Med"},{"key":"5751_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"5751_CR20","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"4","key":"5751_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G van Valkenhoef","year":"2012","unstructured":"van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Res Synth Methods. 2012;3(4):285\u201399.","journal-title":"Res Synth Methods"},{"key":"5751_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"5751_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of Model Complexity and Fit. J Royal Stat Soc Ser B: Stat Methodol. 2002;64(4):583\u2013639.","journal-title":"J Royal Stat Soc Ser B: Stat Methodol"},{"key":"5751_CR24","doi-asserted-by":"publisher","first-page":"1103039","DOI":"10.3389\/fnagi.2023.1103039","volume":"15","author":"K Chen","year":"2023","unstructured":"Chen K, Li H, Yang L, Jiang Y, Wang Q, Zhang J, et al. Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: a systematic review and network meta-analysis. Front Aging Neurosci. 2023;15:1103039.","journal-title":"Front Aging Neurosci"},{"key":"5751_CR25","doi-asserted-by":"publisher","first-page":"e2017047","DOI":"10.4178\/epih.e2017047","volume":"39","author":"S Shim","year":"2017","unstructured":"Shim S, Yoon BH, Shin IS, Bae JM. Network meta-analysis: application and practice using Stata. Epidemiol Health. 2017;39:e2017047.","journal-title":"Epidemiol Health"},{"issue":"2","key":"5751_CR26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","volume":"11","author":"C Yan","year":"2022","unstructured":"Yan C, Duan RS, Yang H, Li HF, Zou Z, Zhang H, et al. Therapeutic effects of Batoclimab in Chinese patients with generalized Myasthenia gravis: a Double-Blinded, randomized, placebo-controlled phase II study. Neurol Ther. 2022;11(2):815\u201334.","journal-title":"Neurol Ther"},{"issue":"16","key":"5751_CR27","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","volume":"90","author":"K Hewett","year":"2018","unstructured":"Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, et al. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425\u201334.","journal-title":"Neurology"},{"issue":"12","key":"5751_CR28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr., Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol"},{"issue":"23","key":"5751_CR29","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr., Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661\u201373.","journal-title":"Neurology"},{"issue":"7","key":"5751_CR30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr., Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"key":"5751_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jocn.2023.11.013","volume":"119","author":"B GomezMancilla","year":"2024","unstructured":"GomezMancilla B, Meriggioli MN, Genge A, Roubenoff R, Espi\u00e9 P, Dupuy C, et al. Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: a phase 2 randomized study. J Clin Neurosci. 2024;119:76\u201384.","journal-title":"J Clin Neurosci"},{"issue":"2","key":"5751_CR32","doi-asserted-by":"publisher","first-page":"e207937","DOI":"10.1212\/WNL.0000000000207937","volume":"102","author":"C Antozzi","year":"2024","unstructured":"Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RJ, et al. Safety and Efficacy of Nipocalimab in patients with generalized Myasthenia Gravis. Neurology. 2024;102(2):e207937.","journal-title":"Neurology"},{"issue":"5","key":"5751_CR33","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, et al. Terminal complement inhibitor ravulizumab in generalized Myasthenia Gravis. NEJM Evid. 2022;1(5):EVIDoa2100066.","journal-title":"NEJM Evid"},{"issue":"6","key":"5751_CR34","doi-asserted-by":"publisher","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","volume":"96","author":"V Bril","year":"2021","unstructured":"Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, et al. Efficacy and safety of Rozanolixizumab in moderate to severe generalized Myasthenia gravis: a phase 2 Randomized Control Trial. Neurology. 2021;96(6):e853\u201365.","journal-title":"Neurology"},{"issue":"5","key":"5751_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383\u201394.","journal-title":"Lancet Neurol"},{"issue":"5","key":"5751_CR36","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard Jr","year":"2020","unstructured":"Howard JF Jr., Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized Myasthenia gravis: results of a phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020;77(5):582\u201392.","journal-title":"JAMA Neurol"},{"issue":"5","key":"5751_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr., Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395\u2013406.","journal-title":"Lancet Neurol"},{"issue":"11","key":"5751_CR38","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, et al. Efficacy and safety of Rituximab for New-Onset generalized Myasthenia gravis: the RINOMAX Randomized Clinical Trial. JAMA Neurol. 2022;79(11):1105\u201312.","journal-title":"JAMA Neurol"},{"issue":"4","key":"5751_CR39","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","volume":"98","author":"RJ Nowak","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, et al. Phase 2 trial of Rituximab in Acetylcholine receptor antibody-positive generalized Myasthenia gravis: the BeatMG Study. Neurology. 2022;98(4):e376\u201389.","journal-title":"Neurology"},{"issue":"9","key":"5751_CR40","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","volume":"82","author":"H Yoshikawa","year":"2011","unstructured":"Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(9):970\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"5751_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","volume":"10","author":"L Zhou","year":"2017","unstructured":"Zhou L, Liu W, Li W, Li H, Zhang X, Shang H, et al. Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China. Ther Adv Neurol Disord. 2017;10(9):315\u201325.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"5751_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","volume":"87","author":"M Pasnoor","year":"2016","unstructured":"Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, et al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology. 2016;87(1):57\u201364.","journal-title":"Neurology"},{"issue":"6","key":"5751_CR43","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, et al. An international, Phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400\u20136.","journal-title":"Neurology"},{"key":"5751_CR44","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1196\/annals.1254.064","volume":"998","author":"MN Meriggioli","year":"2003","unstructured":"Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci. 2003;998:494\u20139.","journal-title":"Ann N Y Acad Sci"},{"key":"5751_CR45","doi-asserted-by":"crossref","unstructured":"Yan C, Yue Y, Guan Y, Bu B, Ke Q, Duan R et al. Batoclimab vs Placebo for generalized Myasthenia gravis: a Randomized Clinical Trial. JAMA Neurol. 2024;81(4):336-345.","DOI":"10.1001\/jamaneurol.2024.0044"},{"issue":"6","key":"5751_CR46","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","volume":"71","author":"A trial of","year":"2008","unstructured":"A trial of. Mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71(6):394\u20139.","journal-title":"Neurology"},{"key":"5751_CR47","doi-asserted-by":"publisher","first-page":"1280226","DOI":"10.3389\/fimmu.2023.1280226","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen H, Qiu Y, Yin Z, Wang Z, Tang Y, Ni H, et al. Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a bayesian network analysis. Front Immunol. 2023;14:1280226.","journal-title":"Front Immunol"},{"key":"5751_CR48","doi-asserted-by":"crossref","unstructured":"Li J, Wu X, Chu T, Tan X, Wang S, Qu R et al. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2024;271(5):2298-2308.","DOI":"10.1007\/s00415-024-12247-x"},{"issue":"2","key":"5751_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40265-022-01826-9","volume":"83","author":"J Flammer","year":"2023","unstructured":"Flammer J, Neziraj T, R\u00fcegg S, Pr\u00f6bstel AK. Immune mechanisms in Epileptogenesis: update on diagnosis and treatment of Autoimmune Epilepsy syndromes. Drugs. 2023;83(2):135\u201358.","journal-title":"Drugs"},{"issue":"12","key":"5751_CR50","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/14712598.2023.2296126","volume":"23","author":"A Matic","year":"2023","unstructured":"Matic A, Alfaidi N, Bril V. An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis. Expert Opin Biol Ther. 2023;23(12):1163\u201371.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"5751_CR51","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/bc.bc_77_21","volume":"8","author":"JP Rissardo","year":"2022","unstructured":"Rissardo JP, Caprara ALF, Durante \u00cd, Rauber A. Lithium-associated movement disorder: a literature review. Brain Circ. 2022;8(2):76\u201386.","journal-title":"Brain Circ"},{"issue":"12","key":"5751_CR52","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","volume":"108","author":"GJ Kahaly","year":"2023","unstructured":"Kahaly GJ, Dolman PJ, Wolf J, Giers BC, Elflein HM, Jain AP, et al. Proof-of-concept and Randomized, Placebo-controlled trials of an FcRn inhibitor, Batoclimab, for thyroid Eye Disease. J Clin Endocrinol Metab. 2023;108(12):3122\u201334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"5751_CR53","first-page":"1637","volume":"18","author":"LN Zhu","year":"2023","unstructured":"Zhu LN, Hou HM, Wang S, Zhang S, Wang GG, Guo ZY, et al. FcRn inhibitors: a novel option for the treatment of myasthenia gravis. Neural Regen Res. 2023;18(8):1637\u201344.","journal-title":"Neural Regen Res"},{"issue":"4","key":"5751_CR54","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.tmrv.2019.09.004","volume":"33","author":"CJ Patriquin","year":"2019","unstructured":"Patriquin CJ, Kuo KHM. Eculizumab and Beyond: the past, Present, and future of complement therapeutics. Transfus Med Rev. 2019;33(4):256\u201365.","journal-title":"Transfus Med Rev"},{"issue":"11","key":"5751_CR55","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843\u201354.","journal-title":"J Clin Invest"},{"issue":"5","key":"5751_CR56","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jnnp-2021-328665","volume":"93","author":"C Nelke","year":"2022","unstructured":"Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N, et al. Eculizumab versus Rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022;93(5):548\u201354.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"5751_CR57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/CND.0000000000000342","volume":"23","author":"C Rodolico","year":"2021","unstructured":"Rodolico C, Bonanno C, Brizzi T, Nicocia G, Trimarchi G, Lupica A, et al. Methotrexate as a steroid-sparing Agent in Myasthenia gravis: a preliminary retrospective study. J Clin Neuromuscul Dis. 2021;23(2):61\u20135.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"5","key":"5751_CR58","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s13760-023-02242-w","volume":"123","author":"MB Prado Jr","year":"2023","unstructured":"Prado MB Jr., Adiao KJB. Methotrexate in generalized myasthenia gravis: a systematic review. Acta Neurol Belg. 2023;123(5):1679\u201391.","journal-title":"Acta Neurol Belg"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05751-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05751-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05751-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T04:04:13Z","timestamp":1729656253000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05751-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5751"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05751-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"13 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"955"}}